Without claiming to be exhaustive, in HER2-positive breast cancer, the combination of trastuzumab and lapatinib significantly outperformed trastuzumab alone, achieving a pathologic complete response (pCR) rate of 51.3% versus 29.5% in the neoadjuvant setting [12]. Here, ERBB2 is linked to breast cancer.